BGB-A317: Immune Checkpoint Inhibitor Against PD-1

BGB-A317 is a monoclonal antibody that belongs to a promising new class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 has the potential to restore a T-cell’s cancer killing ability by inhibiting PD-1 and removing the blockade of immune activation against cancer. We believe BGB-A317 is differentiated from the currently approved PD-1 antibodies with the ability to bind Fc gamma receptor I specifically engineered out, and we believe this could potentially result in improved activities. In addition, BGB-A317 has a unique binding signature to PD-1 with high affinity and superior target specificity.

BGB-A317 is being developed as a monotherapy and in combination for various solid-organ and blood-borne cancers. In our preclinical studies, BGB-A317 has shown a unique PD-1 binding epitopes with high affinity and superior specificity to the target receptor PD-1. It exhibits a potent cellular activity in activating anti-cancer T-lymphocytes. We are currently conducting phase I clinical trial in relapsed or refractory solid tumor patients in Australia. Importantly, we believe BGB-A317 is the first PD-1 antibody that has entered clinical study and is being developed in China under the domestic regulatory pathway.

Mechanism of Action

BGB-A317